Dr. Robert J. Rubin to Join Halt Board as Reimbursement Advisor
LIVERMORE, Calif., July 26 /PRNewswire/ -- Halt Medical, Inc. announced today that Robert J. Rubin, M.D. has been appointed to its Scientific Advisory Board. Dr. Rubin will also be a consultant to the company, helping to develop and implement comprehensive reimbursement strategies. Dr. Rubin's distinguished career has included significant contributions in the fields of medicine, government, and business. Currently, he is Clinical Professor of Medicine at Georgetown University's School of Medicine and serves as a consultant to several international healthcare companies. Among his positions in government, Dr. Rubin served as Assistant Secretary, U.S. Department of Health and Human Services (DHHS), concurrent with his appointment as Assistant Surgeon General from 1981 to 1984. Among his positions in business, Dr. Rubin served as president of the leading healthcare consulting firm, The Lewin Group, Inc., and its predecessor organizations, from 1987 to 2001.
"Dr. Rubin brings to Halt Medical significant medical and business expertise", commented Jeff Cohen, Halt's Chief Executive Officer. "While Dr. Rubin was at the DHHS, he was responsible for passage of Medicare's Prospective Payment System. His guidance will add significant value to Halt, particularly in the areas of public and private sector reimbursement strategies for the Halt Fibroid Procedure".
About Halt Medical, Inc.
Halt Medical, Inc. is a late-stage medical device design and manufacturing company developing products to ablate tissue with its next generation Radiofrequency Volumetric Thermal Ablation (RFVTA) system. The Halt system has been cleared by the FDA for general use and is currently being studied in the US for relief of symptoms caused by uterine fibroids. Halt is preparing to commercialize the Halt Fibroid System in Europe where it has recently obtained the CE mark for general and fibroid indications. The worldwide business opportunity for the Halt Fibroid System is estimated to be over $2 billion annually.
Information about the Halt Fibroid Study and a list of clinical sites in the U.S. may be found at
www.clinicaltrials.gov, study number NCT00874029.
SOURCE Halt Medical, Inc.
More by this Source
Halt Medical Announces Initial Commercial Results; Expanded Launch of Acessa™ System
Apr 01, 2013, 03:00 ET
Halt Medical Announces The First Commercial Use Of the Acessa™ System
Mar 12, 2013, 03:00 ET
The Acessa™ System Now Approved In Mexico To Treat Symptomatic Uterine Fibroids
Feb 11, 2013, 03:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.